Published • loading... • Updated
Biopharma firm BioXcel Therapeutics files for bankruptcy in US
Teva will serve as the stalking horse bidder as BioXcel seeks to sell substantially all assets and keep operations funded with $19 million in DIP financing.
Summary by WTVB
6 Articles
6 Articles
Biopharma firm BioXcel Therapeutics files for bankruptcy in US
·London, United Kingdom
Read Full Article
BioXcel Shares Sink 62% as Chapter 11 Filing Leaves Equity Subordinate to $100M–$500M Debt
NEW HAVEN, August 28, 2026, 05:12 (EDT) BioXcel sought Chapter 11 bankruptcy protection in Delaware on Thursday. Shares dropped by 62.4% to approximately $0.27 in premarket trading, with volume close to 975,000 shares. The petition states that estimated assets range between $10 million and $50 million. Estimated liabilities ranging from $100 million to $500 million…
Coverage Details
Total News Sources6
Leaning Left0Leaning Right2Center3Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
C 60%
R 40%
Factuality
To view factuality data please Upgrade to Premium
